HRMY
NEUTRAL
$28.89
Live
Harmony Biosciences Holdings, Inc. · NASDAQ
Target $42.0
(+45.4%)
$25.52
52W Range
$40.87
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
85%
HRMY presents a dichotomy between a rock-solid balance sheet and deteriorating earnings performance. The Piotroski F-Score of 4/9 indicates stable financial health, supported by an exceptionally low Debt/Equity ratio (0.19) and strong liquidity (Current Ratio 3.60). However, these strengths are offset by a severe -55% YoY earnings contraction and a bearish insider sentiment characterized by C-suite selling. While the stock trades near its Graham Number ($30.21) and boasts an attractive Forward P/E of 4.99, the disconnect between analyst targets ($42.00) and current growth trends suggests significant volatility ahead.
Key Strengths
Very low leverage with a Debt/Equity ratio of 0.19
Strong liquidity position with a Current Ratio of 3.60
High gross profit margins at 77.16%
Attractive valuation metrics, specifically a Forward P/E of 4.99
Consistent double-digit revenue growth (21.10% YoY)
Key Risks
Severe earnings decline (-55% YoY and -64.8% Q/Q EPS growth)
Bearish insider activity with significant selling by the CEO and CFO
Poor recent earnings track record, beating only 1 of the last 4 estimates
Technical trend is currently 0/100 (Bearish)
Current price ($28.89) is significantly above the growth-based intrinsic value ($18.83)
AI Fair Value Estimate
Based on comprehensive analysis
$24.52
-15.1% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare HRMY against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning HRMY from our newsroom.
Newest → oldest
No matching news yet.